Breaking News Headlines Today | Ground News

Holiday Sale — Get 40% off Vantage for yourself or as a gift

Drug Discovery and Development image

News from Drug Discovery and Development

Drug Discovery and Development’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Drug Discovery and Development’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Drug Discovery and Development

Where is Drug Discovery and Development located?Drug Discovery and Development's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Drug Discovery and Development News

Trump Plans to Push for Cannabis Rescheduling as Less Dangerous: Report — REUTERS / pwu404

Marijuana · United States

Trump Plans to Push for Cannabis Rescheduling as Less Dangerous: Report

43% Left coverage: 42 sources

President Donald Trump is expected to direct his administration to move to reclassify marijuana as a less dangerous drug, according to people familiar with the matter, a move that could represent one of the biggest shifts in US policy toward cannabis in decades.See the Story

Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial

Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial

100% Center coverage: 1 sources

Study marks first improvement in adjuvant endocrine therapy for early breast cancer in 20 years See the Story

Recursion’s AI-Selected MEK Drug Cuts FAP Polyp Burden in Small Trial

Recursion’s AI-Selected MEK Drug Cuts FAP Polyp Burden in Small Trial

Recursion Pharmaceuticals dropped phase 1b/2 results Monday for REC-4881, a MEK inhibitor it flagged through AI screens. In 12 older patients (55 years old and older) with familial adenomatous polyposis, the drug trimmed total polyp burden a median 43% after three months. The gains stuck around: 12 weeks off treatment, the median drop climbed to… The post Recursion’s AI-selected MEK drug cuts FAP polyp burden in small trial appeared first on Dru…See the Story

Breaking News Topics Related to Drug Discovery and Development